Understanding and Differentiating ADCs in Solid Tumors

CE / CME

Fundamentals I: Understanding and Differentiating ADCs Targeting HER2, HER3, and TROP2 in Solid Tumors

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: December 03, 2024

Expiration: December 02, 2025

Sara Cooper
Sara Cooper, MSN, RN, ACNP-BC, AOCNP-BC
Kristi K. Orbaugh
Kristi K. Orbaugh, MSN, RNP, AOCNP
Kimberly Podsada
Kimberly Podsada, MSN, NP-C

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Some ADCs have what is known as a “bystander effect” that can cause increased adverse events. What structural difference between ADCs contributes to an increased “bystander effect”?

2.

A patient on T-DXd presents with new moderate shortness of breath, dry cough, and a pulse oximetry reading of 89% on room air. An updated CT scan of the chest shows new diffuse ground glass opacities suspicious for ILD. How would you proceed?

3.

A patient is starting sacituzumab govitecan for HR+/HER2- metastatic breast cancer. What serious adverse events should you discuss with the patient prior to initiation?

4.

How confident are you in your ability to identify and address socioeconomic and geographic barriers to improve therapeutic connections with patients and support their optimal health outcomes?